Clinical trial
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2…
NCT00411892 · Novo Nordisk A/S, Industry · Terminated
Key facts
| NCT number | NCT00411892 |
|---|---|
| Title | Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes |
| Official title | Effect of Inhaled Insulin (AERx® iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes, Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | pioglitazone, inhaled human insulin |
| Enrollment | 196 |
| Start date | Nov 29, 2006 |
| Primary completion | Mar 18, 2008 |
| Completion | Mar 18, 2008 |
| First posted | Dec 15, 2006 |
| Last update posted | Sep 5, 2018 |
| Countries | United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: